In a double-blind trial of 106 adults with acute sciatica from a herniated disc, an ultrasound-guided caudal injection of dexamethasone did not improve disability at 3 weeks, or other outcomes up to…
In a double-blind crossover trial of thirty-one people with type 1 diabetes and kidney disease, 24 weeks of ursodeoxycholic acid did not reduce urine albumin compared with placebo, despite promising results in…
In a placebo-controlled crossover trial of 15 people with fatty liver disease, 6 weeks of a drug that blocks the first step of fructose metabolism improved the liver's response to insulin and…
In a first-in-human trial in 79 healthy adults, the oral drug VES001 was well tolerated and raised levels of progranulin, a protein that is too low in one genetic form of frontotemporal…
In the HIMALAYA trial of 305 people with ALS in 13 countries, the RIPK1 inhibitor SAR443820 did not slow functional decline over 24 weeks and caused more liver enzyme increases than placebo.
In the HEALEY ALS Platform Trial, 325 participants took DNL343 or placebo for 24 weeks. The drug, which targets the cell's integrated stress response, did not slow loss of function or improve…
